Design Therapeutics, Inc. — Director's Dealing 2021

Jun 16, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Design Therapeutics, Inc. (DSGN)
CIK: 0001807120
Period of Report: 2021-06-15

Reporting Person: Prasad Deepa (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-15	Stock Option (right to buy)	$27.04	A	30000	Acquired	2031-06-14	Common Stock (30000)	Direct

Footnotes

F1: The shares subject to the option vest in equal monthly installments over a three year period following June 15, 2021 (the "Grant Date") such that the option is fully vested on the third anniversary of the Grant Date.